MARCOS
GONZÁLEZ DÍAZ
Investigador en el periodo 1993-2023
Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (26)
2021
-
Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative
Annals of Hematology, Vol. 100, Núm. 3, pp. 825-830
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
2016
-
High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma
Annals of Hematology, Vol. 95, Núm. 2, pp. 253-262
-
Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients
PLoS ONE, Vol. 11, Núm. 2
-
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
Leukemia Research, Vol. 40, pp. 1-9
-
Multipronged functional proteomics approaches for global identification of altered cell signalling pathways in B-cell chronic lymphocytic leukaemia
Proteomics, Vol. 16, Núm. 8, pp. 1193-1203
-
Sarcoma histiocítico en intestino delgado: estudio y discusión de un caso con reordenamiento clonal linfoide B
Revista Espanola de Patologia, Vol. 49, Núm. 4, pp. 254-258
2015
2014
-
Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance
Haematologica, Vol. 99, Núm. 1, pp. 155-162
2013
-
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234
2012
-
Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients
Haematologica, Vol. 97, Núm. 8, pp. 1218-1224
-
Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: Antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype
American Journal of Pathology, Vol. 181, Núm. 5, pp. 1879-1888
-
SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status
Leukemia, Vol. 26, Núm. 12, pp. 2521-2529
2011
2010
-
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458
-
Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling
Leukemia, Vol. 24, Núm. 3, pp. 629-637
-
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients
Haematologica, Vol. 95, Núm. 5, pp. 745-751
2009
-
Bisphosphonate-related osteonecrosis: Genetic and acquired risk factors
Oral Diseases, Vol. 15, Núm. 6, pp. 382-387
-
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics
Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709
-
Primary cutaneous T-cell lymphoproliferative disorder of donor origin after allogeneic haematopoietic stem-cell transplantation
Clinical and Experimental Dermatology, Vol. 34, Núm. 8